ArticleJournal of pharmaceutical health care and sciences2025
A cross-sectional survey of knowledge regarding sodium-glucose co-transporter 2 inhibitors (SGLT2is) among primary care physicians and pharmacists in China.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSodium-glucose cotransporter-2 inhibitors (SGLT2is) occupy a pivotal role in the management of Type 2 diabetes due to their unique glucose-lowering mechanism and multiple clinical benefits. Physicians, as decision-makers in treatment, and pharmacists, as disseminators of drug knowledge, play crucial roles in ensuring the effectiveness and safety of treatments involving SGLT2is. However, the extent of primary healthcare workers' understanding of SGLT2i characteristics prior to usage remains unclear.
aimThis study aims to evaluate the level of knowledge pertaining to the use of SGLT2is among primary care physicians and hospital pharmacists.
methodsA field survey on the cognition of SGLT2is was conducted among internal medicine, surgical, general practice, and pharmacy departments within healthcare institutions and community health service centers in Kaihua County, Zhejiang Province, China. An online questionnaire, including demographic information and knowledge about SGLT2is, was designed and administered.
resultsThe survey included 105 physicians and 31 pharmacists, with 59.56% being male and 66.18% holding intermediate or senior professional titles. Scores were predominantly in the range of 9-11 out of a maximum of 16 points, encompassing 102 participants (75.00%), while 9 individuals (11.76%) scored 13 points or higher, and 13 participants (9.56%) scored 8 points or lower. Notably, 33.09% correctly identified that SGLT2is are not applicable for Type 1 diabetes patients, 15.44% correctly noted the need to discontinue SGLT2is before major surgery, 23.53% correctly answered that SGLT2is are not approved in China for treating Type 2 diabetes in children and adolescents, and 47.06% correctly recognized that SGLT2is can be combined with metformin to enhance glucose-lowering effects. Additionally, the average score of physicians in surgical departments was significantly lower than other departments (H = 19.733, P < 0.001), and female participants had significantly higher average scores than males (Z = -3.528, P < 0.001).
conclusionPrimary care physicians and pharmacists in Kaihua County exhibit a robust understanding of the mechanisms of SGLT2is. However, there are notable deficiencies in the management of perioperative care in surgery, in discerning indications across internal and general medicine, in identifying contraindications in special populations, and in the pharmacists' roles in prescription review. These findings suggest a need for targeted educational initiatives to enhance understanding and safe use of SGLT2 inhibitors at the primary-care level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.